Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 6, 2025Cardiovascular Research

Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF

View Full Paper
Ask AI
Bookmark
Share

Authors

ITInês ToméDPDaniel Pereira-SousaDMDaniela Miranda‐Silva

Discussion

Loading...

Member takes

Overview

Administration of senolytic therapy improves renal function and reduces inflammation in HFpEF, suggesting a potential treatment pathway.

Key Points

  • Cardiac fibrosis decreased and renal function improved following senolytic treatment in HFpEF.
  • Senolytic therapy reduced B-type natriuretic peptide levels and endothelial damage in ZSF1-Obese rats.
  • Observational analysis of systemic inflammation highlighted immune dysregulation in patients with HFpEF.
  • Findings suggest senotherapeutics may be a valuable therapy for combating inflammation in heart failure.

Cite This Study

Tomé et al. (2025) studied this question.

synapsesocial.com/papers/69337cfbb3f947a0a125a4f4https://doi.org/10.1093/cvr/cvaf208
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract Wed077: The role of senescence in HFpEF induced by cardiometabolic syndrome2025
  2. 2Inflammation dominance over senescence is a conserved feature across heart diseases2026
  3. 3Abstract Wed082: Integrated Systems Biology Identifies Disruptions In Mitochondrial Function And Metabolism As Key Contributors To HFpEF2025
  4. 4Abstract Fri049: Exploring the Role of Interferon Responsive Neutrophils in the Development of HFpEF2025
  5. 5Abstract Wed091: Biomechanical and Transcriptomic Remodeling of the Heart in Heart Failure with Preserved Ejection Fraction2025